Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

DoT wing seeks clarity on 3G licence fees
Wireless Planning and Coordination (WPC) wing, the highest policymaking wing of the Department of Telecommunications (DoT), has sought clarifications from the department on the licence fees that need to be paid by successful bidders of third generation (3G) auction for acquiring a unified access service licence (UASL).

VW's Polo to come with customised features
German auto major Volkswagen today said it will offer package options to customers of its soon-to-be launched small car Polo, which will include features like accessories, safety and sports, and entertainment systems.

News of the day

Sun TV up on restructuring plans
Sun TV ended at Rs 333, higher by 0.2%, on the BSE. The stock opened at Rs 336, which was also the day"s high and a low of Rs 333.
Online Business

SC refuses relief to Roche on patent plea against Cipla

The Supreme Court today refused to give any relief to Swiss pharma firm Hoffman La Roche Ltd that had challenged a Delhi High Court order allowing Cipla to manufacture and sell a generic version of lung cancer drug "Erlotinib". - SC to commence final hearing on Ambani gas row on Oct 20 - Govt for filling up vacancies of judges in SC, HC - SC upholds law on office of profit - SC restores powers to Prasar Bharati CEO - SC pulls up Ranbaxy for delayed raising of refund issue - SC pulls up Ranbaxy for delayed raising of refund issue A bench headed by Justice Dalveer Bhandari, while disposing of Roche"s plea, said that it was not inclined to give any relief and asked the single judge of the High Court, before whom the original petition is pending, to decide the matter expeditiously. Besides, it said that the single judge should not be influenced by any observations made by the division bench. The division bench of the High Court besides imposing a cost of Rs five lakh on the Swiss Company had also dismissed its plea seeking to restrain Cipla from manufacturing and selling the generic drug till the issue of patent rights was decided through litigation.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009